생화학분자생물학회

	Laurent Poulain ( l.poulain@baclesse.unicancer.fr )
	2017-present	Deputy Director of Inserm U1086 ANTICIPE, University of Caen Normandy, France
	2015-2017	Head director of Inserm U1199 BioTICLA, University of Caen Normandy, France
	2012-2015	Head director of EA4656 BioTICLA, University of Caen Normandy, France
	2003-2012	Director of research team BioTICLA (EA1772 GRECAN laboratory), University of Caen Normandy, France
	1999-2001	Postdoctoral fellow, CNRS UMR7514, University of Strasbourg, France
	1994-1997	PhD, EA1772 GRECAN laboratory, University of Caen Normandy, France
	Louis-Bastien Weiswald ( lb.weiswald@baclesse.unicancer.fr )
	2020-present	Researcher, Inserm U1086 ANTICIPE, University of Caen Normandy, France
	2018-2020	Temporary Lecturer and Research Assistant, Inserm U1086 ANTICIPE, University of Caen Normandy, France
	2017-2018	Postdoctoral fellow, Inserm U1086 ANTICIPE, University of Caen Normandy, France
	2014-2013	Postdoctoral fellow, Michael Smith Genome Sciences Centre, BC Cancer Agency, Canada
	2011-2012	Postdoctoral fellow, Laboratory of Onconbiology, René Huguenin Hospital, Curie Institute, France
	2007-2010	PhD, Laboratory of Liver pathophysiology CNRS UMR8149, Faculty of Pharmaceutical and Biological Sciences, Paris Descartes University, France

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology

Over the past decade, the emergence of patient-derived tumor organoids (PDTOs) has broadened the repertoire of preclinical models and progressively revolutionized three-dimensional cell culture in oncology. PDTO can be grown from patient tumor samples with high efficiency and faithfully recapitulates the histological and molecular characteristics of the original tumor. Therefore, PDTOs can serve as invaluable tools in oncology research, and their translation to clinical practice is exciting for the future of precision medicine in oncology. In this review, we provide an overview of methods for establishing PDTOs and their various applications in cancer research, starting with basic research and ending with the identification of new targets and preclinical validation of new anticancer compounds and precision medicine. Finally, we highlight the challenges associated with the clinical implementation of PDTO, such as its representativeness, success rate, assay speed, and lack of a tumor microenvironment. Technological developments and autologous cocultures of PDTOs and stromal cells are currently ongoing to meet these challenges and optimally exploit the full potential of these models. The use of PDTOs as standard tools in clinical oncology could lead to a new era of precision oncology in the coming decade.

Exp Mol Med. 2024 Jul;56(7):1531-1551. doi: 10.1038/s12276-024-01272-5
https://www.ncbi.nlm.nih.gov/pubmed/38945959